Thus, the enhanced generation and LN migration of DCs with elevated anti-tumour T cell-priming capacity upon MK2 deficiency gives rise to an overall improved tumour-targeted cytotoxic T cell response, as indicated by robust accumulation of CD8+ T cells at the tumour site. This evidence concerns the gene CD8A and neoplasm.